加载中
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
前收盘价
US$7.77
−US$0.30 · -3.72%
盘前
US$7.75
−US$0.02 · -0.26%
10月13日 9:01 ET
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
42
合理估值
情绪
68
看涨
风险
47
风险偏高
动量
77
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
日内区间
当前US$7.77
52周区间
当前US$7.77
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.7亿 USD | 8332.8万 USD | 9024.2万 USD | 1.13亿 USD | 4.7亿 USD |
| 销货成本 | 2029.8万 USD | 3356.7万 USD | 3721.3万 USD | 5454.5万 USD | 5183.3万 USD |
| 毛利 | 1.5亿 USD | 4976.1万 USD | 5302.9万 USD | 5817.9万 USD | 4.19亿 USD |
| 研究与开发 | 2.28亿 USD | 2.09亿 USD | 2.32亿 USD | 2.42亿 USD | 1.81亿 USD |
| 销售、一般及管理费用 | 8286.3万 USD | 7661.9万 USD | 8849.4万 USD | 8528.1万 USD | 7933.3万 USD |
| 营业费用 | 3.11亿 USD | 2.83亿 USD | 3.21亿 USD | 3.21亿 USD | 2.59亿 USD |
| 利息收入 | 1226.6万 USD | 17.4万 USD | 2.5万 USD | 34.2万 USD | 71.9万 USD |
| 利息支出 | 4500.8万 USD | 1265.9万 USD | 686.2万 USD | 2325.4万 USD | 2627.7万 USD |
| 折旧和摊销 | 1561.5万 USD | 1621.5万 USD | 1732万 USD | 1290.9万 USD | 956.4万 USD |
| 营业利润 | −1.61亿 USD | −2.33亿 USD | −2.68亿 USD | −2.63亿 USD | 1.6亿 USD |
| 净利润 | −1.94亿 USD | −2.27亿 USD | −2.63亿 USD | −2.8亿 USD | 1.28亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$20.00
上涨空间 157.40%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1676.98万0.00%2.3万亿 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI1574.08万0.16%103.03亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM1242.33万0.02%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF534.81万0.01%954亿 USD0.05%US$233.52-0.63%
Fidelity Enhanced Small Cap ETFFESM383.75万0.06%64.1亿 USD0.28%US$45.24-0.48%
iShares Biotechnology ETFIBB382.32万0.04%108.2亿 USD0.44%US$204.26-1.08%
iShares Russell 2000 Growth ETFIWO367.54万0.03%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO263.25万0.01%180亿 USD0.06%US$112.27-0.35%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
